Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 64

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 3
Chunk 64
---
 ability to acquire, in-license or use such
third-party proprietary rights.

The licensing and acquisition
of third-party intellectual property rights is a competitive practice, and companies that may be more established, or have greater resources
than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary
or attractive for commercializing our product candidates. More established companies may have a competitive advantage over us due to their
larger size and cash resources or greater clinical development and commercialization capabilities. There can be no assurance that we will
be able to successfully complete such negotiations and ultimately acquire the rights to the intellectual property surrounding the additional
product candidates that we may seek to acquire. We may be unable to acquire or in-license methods of use, processes or other intellectual
property rights from third parties that we identify as necessary or important to our business operations. If we fail to obtain any of
these licenses at a reasonable cost or on reasonable terms, if at all, it would harm our business. We may need to cease use of the compositions
or methods covered by such third-party intellectual property rights, and/or may need to seek to develop alternative approaches that do
not infringe on such intellectual property rights which may entail additional costs and development delays, even if it is possible and
we were able to develop such alternatives.

Even if we are able to obtain
a license, it may be non-exclusive, thereby giving our competitors access to the same technologies that we have licensed. In that event,
we may be required to expend significant time and resources to develop or license replacement technologies. Moreover, we may need to rely
on our future licensors to obtain, maintain and enforce patent rights for the licensed intellectual property; however, they may not successfully
prosecute, maintain or enforce such licensed intellectual property. We may have limited control over the manner in which our future licensors
initiate an infringement proceeding against a third-party infringer of the intellectual property rights, or defend certain of the intellectual
property that is licensed to us. It is possible that the future licensors’ infringement proceeding or defense activities may be
less vigorous than had we conducted them ourselves. Further, our future licensors may retain certain rights under their agreements with
us, including the right to use the underlying technology for noncommercial academic and research use, to publish general scientific findings
from research related to the technology, and to make customary scientific and scholarly disclosures of information relating to the technology.
It would be difficult to monitor whether our future licensors limit